Neutrisci Announces Partnership With Rogers Cup Presented by National Bank

NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSXV:NU) (OTCQB:NRXCF) (FRANKFURT:1N9) the innovator and pioneer behind neuenergy®, is pleased to announce that it has entered into a sponsorship partnership with the Women’s Edition of the 2018 Rogers Cup presented by National Bank.

The Rogers Cup, which will be held in Montreal from August 3 – 12, 2018, was identified as an ideal fit for neuenergy® and our primary consumer base of professionals with an active, healthy lifestyle. Over 180,000 spectators are anticipated over the course of the 10-day tournament.

In keeping with NeutriSci’s mission to bring awareness of neuenergy® to as many people as possible, neuenergy® will be featured as a Bronze Sponsor of the tournament, with a dedicated booth in the spectator’s gallery.   Genie Bouchard and several other neuenergy® Olympic ambassadors will be on-hand to sign autographs and promote neuenergy®. Rogers Cup participants will be able to sample and experience neuenergy® in the retail area on site.

NeutriSci’s CEO, Glen Rehman stated, “We are excited to be participating as a sponsor of the Rogers Cup presented by National Bank.  This partnership reflects our commitment to celebrating the benefits of a healthy, active lifestyle while giving consumers the opportunity to discover our products in an exciting new environment.”

Further to the Company’s news release on March 28, 2018, the Company also announces that it has issued 162,936 common shares to Lexaria Bioscience Corp. (“Lexaria”) pursuant to its Licensing Agreement with Lexaria.  The securities have a hold period expiring August 4, 2018.

On Behalf of the Board of Directors of

NEUTRISCI INTERNATIONAL INC.

Glen Rehman

CEO

NeutriSci International Inc.

Tel: (403) 264-6320

Email: grehman@neutrisci.com

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.

Neuenergy® contains a unique patented combination of blueberries (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.

For more information, please visit: www.neutrisci.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Statements in this press release have not been evaluated by the Food and Drug Administration.  Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.

Source: www.nasdaq.com